By Chelsea Naso ( March 1, 2019, 8:33 PM EST) -- Starboard Value's plans to gain Bristol-Myers Squibb board seats and halt the pharmaceutical company's "poorly conceived and ill-advised" $74 billion takeover of Celgene marks the latest activist challenge to a big-ticket deal, but it's one of the few that's not just after more cash....
Law360 is on it, so you are, too.
A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.
A Law360 subscription includes features such as
- Daily newsletters
- Expert analysis
- Mobile app
- Advanced search
- Judge information
- Real-time alerts
- 450K+ searchable archived articles
And more!
Experience Law360 today with a free 7-day trial.